{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rebif&page=2",
    "query": {
      "intervention": "Rebif",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rebif&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T19:38:25.251Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02019550",
      "title": "Rebif® Rebidose® Versus Rebiject II® Ease-of-Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Rebif Rebidose",
          "type": "DEVICE"
        },
        {
          "name": "Rebiject II",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 97,
      "start_date": "2014-03",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 21,
      "location_summary": "Cullman, Alabama • Tuscon, Arizona • Newport Beach, California + 18 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Dover",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019550"
    },
    {
      "nct_id": "NCT00048347",
      "title": "Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "AVONEX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2002-10",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2010-09-08",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048347"
    },
    {
      "nct_id": "NCT04032158",
      "title": "Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Evobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Avonex®",
          "type": "DRUG"
        },
        {
          "name": "Avonex® matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Evobrutinib matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 3,
      "start_date": "2019-08-26",
      "completion_date": "2020-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032158"
    },
    {
      "nct_id": "NCT00179478",
      "title": "Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Optic Neuritis",
        "Transverse Myelitis",
        "Acute Brainstem/Cerebellar Syndrome"
      ],
      "interventions": [
        {
          "name": "interferon beta 1a 30 ug IM once weekly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2001-02",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 20,
      "location_summary": "Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Elk Grove",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179478"
    },
    {
      "nct_id": "NCT00618527",
      "title": "Combination Therapy Using Cellcept and Rebif in RRMS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "mycophenolate mofetil (Cellcept)",
          "type": "DRUG"
        },
        {
          "name": "human interferon beta 1a (Rebif)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aaron Boster",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2006-08",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-11-15",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00618527"
    },
    {
      "nct_id": "NCT03424733",
      "title": "Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Plegridy",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Tylenol Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Holy Name Medical Center, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-09-25",
      "completion_date": "2020-05-31",
      "has_results": false,
      "last_update_posted_date": "2019-08-15",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 1,
      "location_summary": "Teaneck, New Jersey",
      "locations": [
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03424733"
    },
    {
      "nct_id": "NCT02283853",
      "title": "Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        },
        {
          "name": "Interferon β-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 156,
      "start_date": "2014-08-28",
      "completion_date": "2025-07-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02283853"
    },
    {
      "nct_id": "NCT00914758",
      "title": "Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Washington Neuropsychology Research Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "25 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-03",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2009-06-05",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 7,
      "location_summary": "Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Berkely",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Latham",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00914758"
    },
    {
      "nct_id": "NCT00436826",
      "title": "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Interferon-beta (IFN-beta)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 172,
      "start_date": "2006-11-30",
      "completion_date": "2012-03-31",
      "has_results": true,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 21,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436826"
    },
    {
      "nct_id": "NCT02125578",
      "title": "A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "BIIB017 (PEGylated Interferon Beta-1a)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 69,
      "start_date": "2008-03",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-09-09T19:38:25.251Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02125578"
    }
  ]
}